Welcome to our dedicated page for Y-mAbs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-mAbs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel, antibody-based therapeutic products for cancer treatment. The company focuses on addressing unmet medical needs, particularly in pediatric oncology, and aims to become a leader in this field.
The company's advanced product pipeline includes two pivotal-stage product candidates: naxitamab and omburtamab. Naxitamab targets tumors expressing GD2, while omburtamab targets those expressing B7-H3. Y-mAbs' flagship FDA-approved product, DANYELZA® (naxitamab-gqgk), is a recombinant humanized immunoglobulin G subtype 1k monoclonal antibody designed to treat relapsed or refractory high-risk neuroblastoma in bone or bone marrow.
Y-mAbs is also pioneering novel technologies such as the investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT) platform and bispecific antibodies generated via the Y-BiClone platform. These innovative approaches aim to deliver optimal cancer therapy with minimal toxicity, leveraging existing infrastructure and enhancing patient care.
Financially, Y-mAbs has shown robust performance with increasing revenues from DANYELZA. For the fourth quarter of 2023, the company reported DANYELZA net product revenues of $23.4 million, up 42% year-over-year. The annual revenue reached $84.3 million, marking a 71% increase over the previous year. As of December 31, 2023, the company has delivered DANYELZA to 58 centers across the U.S.
In the first quarter of 2024, Y-mAbs continued its upward trajectory with U.S. DANYELZA net product revenues amounting to $18.6 million. The company maintains a strong financial foundation with approximately $75.7 million in cash and cash equivalents as of March 31, 2024, expected to support operations into 2027.
Y-mAbs collaborates with renowned institutions like Memorial Sloan Kettering Cancer Center (MSK), with exclusive licenses for technologies developed by MSK researchers. This ongoing partnership enhances Y-mAbs' capabilities in advancing their innovative therapeutic platforms.
The company's mission is clear: to transform cancer treatment outcomes by providing better and safer therapies for both children and adults. With continued advancements and strategic partnerships, Y-mAbs remains at the forefront of biopharmaceutical innovation.
Y-mAbs Therapeutics (Nasdaq: YMAB) will host a virtual R&D day on December 16, 2020, from 12 PM to 2 PM ET. Key Opinion Leaders, including Dr. Shakeel Modak from Memorial Sloan Kettering, will present topics on DANYELZA® (naxitamab-gqgk) and its combination with chemotherapy, along with updates on other studies related to osteosarcoma and DIPG. Management will detail advancements regarding their bispecific antibody, nivatrotamab, and additional products. Participants can register for the event online.
Y-mAbs Therapeutics (Nasdaq: YMAB) has partnered with Takeda Israel to establish an exclusive license and distribution agreement for DANYELZA and omburtamab in Israel. DANYELZA, which received FDA approval on November 25, 2020, treats relapsed/refractory high-risk neuroblastoma. Meanwhile, Y-mAbs plans to resubmit the BLA for omburtamab by early 2021. This agreement will facilitate access to these critical treatments for pediatric patients in Israel and surrounding regions, addressing unmet medical needs.
Y-mAbs Therapeutics announced FDA approval for DANYELZA (naxitamab-gqgk) 40mg/10ml, indicated for treating high-risk neuroblastoma in patients aged one and older. DANYELZA, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), targets GD2, a ganglioside in neuroectoderm-derived tumors. This accelerated approval requires further clinical trials to confirm benefits. DANYELZA is expected in U.S. markets soon, supported by two pivotal studies showing manageable adverse events, enhancing Y-mAbs' oncology product pipeline.
Y-mAbs Therapeutics announced a clinical update on its treatment, omburtamab, for diffuse intrinsic pontine glioma (DIPG) during the SNO Virtual Annual Meeting. Data from a Phase 1 study indicated that repeated convection enhanced delivery (CED) infusions are feasible in pediatric patients. The study involved seven patients receiving multiple infusions without negatively impacting procedural aspects. Y-mAbs plans a multicenter Phase 2 trial aimed at improving outcomes for DIPG patients.
Y-mAbs Therapeutics reported a net loss of $32.8 million or ($0.82) per share for Q3 2020, compared to a $23.9 million loss in Q3 2019. Research and development expenses rose to $21.0 million, while general and administrative costs increased to $11.6 million.
Despite the financial losses, Y-mAbs is progressing with its pipeline, including a planned resubmission of the omburtamab BLA and advancements in nivatrotamab, which received Orphan Drug and Rare Pediatric Disease designations from the FDA.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) will report its financial results for Q3 2020 on November 5, 2020, after U.S. market close. A conference call will follow on November 6, 2020, at 9 a.m. ET, featuring Thomas Gad, Dr. Claus Moller, and Bo Kruse. Y-mAbs focuses on developing antibody-based therapies for cancer, with key candidates naxitamab and omburtamab targeting GD2 and B7-H3 tumors, respectively. The press release includes forward-looking statements regarding the company's business model, clinical trials, and potential risks related to financial conditions and product development.
Y-mAbs Therapeutics (Nasdaq: YMAB) announced FDA clearance for its Investigational New Drug (IND) application for 177Lu-omburtamab-DTPA. This treatment targets B7-H3 positive CNS and Leptomeningeal Metastasis in adult patients. The company plans to initiate a Phase 1/2 clinical trial in Q4 2020, leveraging experience from treating adults with 131I-omburtamab. Y-mAbs aims to address unmet medical needs in brain metastasis and expand its clinical reach.
Y-mAbs Therapeutics (YYMB) announced significant clinical updates on its therapies naxitamab and omburtamab at the SIOP Virtual Annual Congress. Naxitamab demonstrated a 68% overall response rate, with 59% achieving complete responses in a pivotal study of 22 patients. Meanwhile, omburtamab showed a promising 87% overall survival rate at 12 months in a study of 17 patients, compared to 30% in a historical control. The FDA has set a PDUFA date for naxitamab on November 30, 2020, indicating potential market entry for these novel cancer treatments.
Y-mAbs Therapeutics has received FDA clearance for its Investigational New Drug application for 177Lu-omburtamab-DTPA, aimed at treating medulloblastoma, a common childhood brain cancer. This product utilizes a radiolabeled antibody and is scheduled for a Phase 1/2 clinical trial targeting pediatric patients later in 2020. The company plans to also initiate a separate trial for adults with B7-H3 positive CNS/LM cancers. The omburtamab antibody was developed by Memorial Sloan Kettering, which has financial interests in Y-mAbs.
Y-mAbs Therapeutics (Nasdaq: YMAB) announced the FDA's grant of Orphan Drug Designation and Rare Pediatric Disease Designation for its bispecific antibody nivatrotamab, aimed at treating neuroblastoma. This designation provides potential market exclusivity of seven years post-approval and eligibility for a Priority Review Voucher. Currently in Phase 1 trials, nivatrotamab is developed in collaboration with Memorial Sloan Kettering Cancer Center and will expand into Phase 2 studies for neuroblastoma and osteosarcoma, as well as a new study in small cell lung cancer expected to begin in Q4 2020.
FAQ
What is the current stock price of Y-mAbs Therapeutics (YMAB)?
What is the market cap of Y-mAbs Therapeutics (YMAB)?
What is Y-mAbs Therapeutics, Inc.?
What products does Y-mAbs offer?
What are Y-mAbs' key technologies?
What recent financial results has Y-mAbs reported?
How many centers are using DANYELZA?
What is Y-mAbs' mission?
Who are Y-mAbs' notable collaborators?
What is the SADA PRIT platform?
How is Y-mAbs financially positioned?
What future developments are expected from Y-mAbs?
